Neurodegenerative Disease Research Creates New Opportunities in the CNS Therapeutics Market

The global CNS therapeutics market size was valued at USD 150.58 billion in 2025 and is projected to grow from USD 165.46 billion in 2026 to USD 351.59 billion by 2034, registering a CAGR of 9.88% during the forecast period (2026–2034).

The CNS therapeutics market is experiencing substantial growth due to the increasing prevalence of neurological disorders, psychiatric conditions, and neurodegenerative diseases worldwide. Growing awareness regarding mental health, advancements in neuroscience research, and the development of innovative treatment approaches are transforming the therapeutic landscape for central nervous system disorders.

Pharmaceutical and biotechnology companies are significantly expanding investments in drug discovery programs targeting conditions such as Alzheimer’s disease, Parkinson’s disease, epilepsy, depression, schizophrenia, multiple sclerosis, and other neurological disorders. The emergence of precision medicine, biologics, and next-generation therapies is further supporting market expansion and improving patient outcomes across diverse treatment areas.

Key Highlights

The global CNS therapeutics market size was valued at USD 150.58 billion in 2025.
The market is projected to grow from USD 165.46 billion in 2026 to USD 351.59 billion by 2034.
The market is expected to register a CAGR of 9.88% during the forecast period (2026–2034).
North America holds the largest share of the global CNS therapeutics market.
Asia-Pacific is the fastest-growing regional market during the forecast period.
By disease type, Neurodegenerative Disorders account for the largest market share.
By drug class, Antidepressants remain one of the largest revenue-generating segments.
Biologics and Targeted Therapies are among the fastest-growing therapeutic categories.
Increasing investments in neuroscience research continue to drive CNS therapeutics market growth.

CNS Therapeutics Market Dynamics

Market Driver

A key driver of CNS therapeutics market growth is the rising incidence of neurological and psychiatric disorders worldwide. Aging populations, lifestyle changes, and increasing awareness of mental health conditions have contributed to a growing demand for effective therapeutic solutions. Diseases such as Alzheimer’s, Parkinson’s, epilepsy, depression, anxiety, and multiple sclerosis continue to create substantial healthcare challenges, encouraging ongoing pharmaceutical innovation.

Additionally, advancements in neuroscience research and diagnostic technologies are improving the understanding of disease mechanisms and enabling the development of more targeted treatment options. The growing availability of novel therapeutics and personalized medicine approaches is enhancing treatment efficacy and expanding the market’s long-term growth potential.

Market Restraint

Despite significant progress, the CNS therapeutics market faces challenges related to the complexity of neurological disorders and lengthy drug development processes. CNS drug candidates often encounter high clinical trial failure rates due to difficulties in demonstrating efficacy and overcoming biological barriers such as the blood-brain barrier.

Furthermore, stringent regulatory requirements and high research and development costs can increase commercialization timelines and financial risks for pharmaceutical companies. Limited treatment effectiveness for certain neurological conditions also remains a challenge across the healthcare sector.

Market Opportunity

The increasing adoption of precision medicine and biomarker-driven therapies presents substantial opportunities for market participants. Advances in genomics, artificial intelligence, and neuroscience are enabling more personalized treatment strategies that improve patient outcomes while reducing adverse effects.

Moreover, expanding investments in neurodegenerative disease research and emerging therapies such as gene therapy, cell therapy, and monoclonal antibodies are expected to create new growth avenues. The growing focus on early diagnosis and disease-modifying treatments is likely to further accelerate innovation across the CNS therapeutics market.

Top Market Players

Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Eli Lilly and Company
Johnson & Johnson
AbbVie Inc.
Merck & Co., Inc.
Bristol Myers Squibb Company
Biogen Inc.
Teva Pharmaceutical Industries Ltd.
Otsuka Pharmaceutical Co., Ltd.
UCB S.A.
Sanofi S.A.
AstraZeneca PLC

Market Segmentation

By Disease Type

Neurodegenerative Disorders
Mental Health Disorders
Epilepsy
Multiple Sclerosis
Parkinson’s Disease
Alzheimer’s Disease
Others

By Drug Class

Antidepressants
Antipsychotics
Antiepileptics
Analgesics
CNS Stimulants
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Regional Analysis

North America

United States
Canada
Mexico

Europe

Germany
United Kingdom
France
Italy
Spain
Rest of Europe

Asia-Pacific

China
Japan
India
South Korea
Australia
Southeast Asia
Rest of Asia-Pacific

Middle East & Africa

Saudi Arabia
UAE
South Africa
Rest of Middle East & Africa

Latin America

Brazil
Argentina
Rest of Latin America

Unlock Full Report Insights and Strategic Analysis- https://straitsresearch.com/report/cns-therapeutics-market

Comprehensive CNS therapeutics market size analysis and forecasts
Detailed market share and competitive landscape assessment
Growth opportunities across neurological and psychiatric treatment segments
Emerging neuroscience and drug development trends
Strategic profiles of leading pharmaceutical companies
Segment-wise revenue forecasts through 2034
Regulatory landscape and innovation outlook
Future opportunities in precision medicine and neurodegenerative disease treatment

About Us

Straits Research is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & market research reports.